219 related articles for article (PubMed ID: 29260253)
1. Rates of glycaemic deterioration in a real-world population with type 2 diabetes.
Donnelly LA; Zhou K; Doney ASF; Jennison C; Franks PW; Pearson ER
Diabetologia; 2018 Mar; 61(3):607-615. PubMed ID: 29260253
[TBL] [Abstract][Full Text] [Related]
2. Distinct trajectories of HbA
Rathmann W; Schwandt A; Hermann JM; Kuss O; Roden M; Laubner K; Best F; Ebner S; Plaumann M; Holl RW;
Diabet Med; 2019 Nov; 36(11):1468-1477. PubMed ID: 31392761
[TBL] [Abstract][Full Text] [Related]
3. Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial.
Punthakee Z; Miller ME; Simmons DL; Riddle MC; Ismail-Beigi F; Brillon DJ; Bergenstal RM; Savage PJ; Hramiak I; Largay JF; Sood A; Gerstein HC;
Diabetologia; 2014 Oct; 57(10):2030-7. PubMed ID: 24985147
[TBL] [Abstract][Full Text] [Related]
4. Weight gain in insulin-treated patients by body mass index category at treatment initiation: new evidence from real-world data in patients with type 2 diabetes.
Paul SK; Shaw JE; Montvida O; Klein K
Diabetes Obes Metab; 2016 Dec; 18(12):1244-1252. PubMed ID: 27502528
[TBL] [Abstract][Full Text] [Related]
5. Mean HbA
Forbes A; Murrells T; Mulnier H; Sinclair AJ
Lancet Diabetes Endocrinol; 2018 Jun; 6(6):476-486. PubMed ID: 29674135
[TBL] [Abstract][Full Text] [Related]
6. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
Montvida O; Shaw JE; Blonde L; Paul SK
Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608
[TBL] [Abstract][Full Text] [Related]
7. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
Shepherd MH; Shields BM; Hudson M; Pearson ER; Hyde C; Ellard S; Hattersley AT; Patel KA;
Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
[TBL] [Abstract][Full Text] [Related]
9. Changes in HbA1c level over a 12-week follow-up in patients with type 2 diabetes following a medication change.
Hirst JA; Stevens RJ; Farmer AJ
PLoS One; 2014; 9(3):e92458. PubMed ID: 24667212
[TBL] [Abstract][Full Text] [Related]
10. Patient-level predictors of achieving early glycaemic control in Type 2 diabetes mellitus: a population-based study.
Svensson E; Baggesen LM; Thomsen RW; Lyngaa T; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
Diabet Med; 2016 Nov; 33(11):1516-1523. PubMed ID: 27412570
[TBL] [Abstract][Full Text] [Related]
11. Effect of diabetes duration on the relationship between glycaemic control and risk of death in older adults with type 2 diabetes.
Ghouse J; Isaksen JL; Skov MW; Lind B; Svendsen JH; Kanters JK; Olesen MS; Holst AG; Nielsen JB
Diabetes Obes Metab; 2020 Feb; 22(2):231-242. PubMed ID: 31596048
[TBL] [Abstract][Full Text] [Related]
12. Changes in HbA1c and frequency of measuring HbA1c and adjusting glucose-lowering medications in the 10 years following diagnosis of type 2 diabetes: a population-based study in the UK.
Lind M; Pivodic A; Cea-Soriano L; Nerman O; Pehrsson NG; Garcia-Rodriguez LA
Diabetologia; 2014 Aug; 57(8):1586-94. PubMed ID: 24811709
[TBL] [Abstract][Full Text] [Related]
13. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
[TBL] [Abstract][Full Text] [Related]
14. Temporal changes in glycaemic thresholds for treatment intensification in type 2 diabetes in an urban Australian setting: the Fremantle Diabetes Study.
Davis TME; Chubb SAP; Curtis BH; Barraclough H; Davis WA
Intern Med J; 2018 Oct; 48(10):1215-1221. PubMed ID: 29230931
[TBL] [Abstract][Full Text] [Related]
15. Short-term progression of cardiometabolic risk factors in relation to age at type 2 diabetes diagnosis: a longitudinal observational study of 100,606 individuals from the Swedish National Diabetes Register.
Steinarsson AO; Rawshani A; Gudbjörnsdottir S; Franzén S; Svensson AM; Sattar N
Diabetologia; 2018 Mar; 61(3):599-606. PubMed ID: 29318343
[TBL] [Abstract][Full Text] [Related]
16. Impact of insulin initiation on glycaemic variability and glucose profiles in a primary healthcare Type 2 diabetes cohort: analysis of continuous glucose monitoring data from the INITIATION study.
Manski-Nankervis J; Yates CJ; Blackberry I; Furler J; Ginnivan L; Cohen N; Jenkins A; Vasanthakumar S; Gorelik A; Young D; Best J; O'Neal D
Diabet Med; 2016 Jun; 33(6):803-11. PubMed ID: 26435033
[TBL] [Abstract][Full Text] [Related]
17. Early glycaemic control among patients with type 2 diabetes and initial glucose-lowering treatment: a 13-year population-based cohort study.
Thomsen RW; Baggesen LM; Svensson E; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
Diabetes Obes Metab; 2015 Aug; 17(8):771-80. PubMed ID: 25929277
[TBL] [Abstract][Full Text] [Related]
18. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.
Alvarez Guisasola F; Mavros P; Nocea G; Alemao E; Alexander CM; Yin D
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():8-15. PubMed ID: 18435669
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of insulin therapy in people with Type 2 diabetes in the Hoorn Diabetes Care System.
Mast MR; Walraven I; Hoekstra T; Jansen AP; van der Heijden AA; Elders PJ; Heine RJ; Dekker JM; Nijpels G; Hugtenburg JG
Diabet Med; 2016 Jun; 33(6):794-802. PubMed ID: 26946450
[TBL] [Abstract][Full Text] [Related]
20. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA
Young TK; Li JW; Kang A; Heerspink HJL; Hockham C; Arnott C; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine M
Diabetologia; 2021 Nov; 64(11):2402-2414. PubMed ID: 34448033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
